Testing GP681 Tablets for Flu in High-Risk Patients
Part of Infections, Lungs & breathing clinical trials.
This study tests an oral tablet called GP681 for people with flu who are at higher risk of serious complications. It compares the new drug to a placebo to see if it helps reduce symptoms faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have a positive flu test and symptoms started within the last 48 hours.
- You currently have a fever and at least one moderate body symptom (like headache or muscle aches) and one moderate respiratory symptom (like cough or sore throat).
- You have a condition that makes flu complications more likely, such as asthma, diabetes, heart disease, a weakened immune system, or you are 65 or older.
- You have not taken any flu antivirals in the past 2 weeks or had a flu shot in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares antiviral medicines in adults who have early, flu-like symptoms and test positive for influenza. It aims to see which antiviral treatment works best and is safe for people treated soon after symptoms start.
This trial tests a new quadrivalent influenza (flu) vaccine in adults 18 and older. It aims to see if the vaccine is safe and helps protect against the flu. You may be able to join if you are generally healthy and have not had the flu or a flu shot recently.
This study tests a new antiviral pill, GP681, to prevent the flu in people who live with someone who has the flu. If you haven't gotten sick yet and are otherwise healthy, this might help keep you from catching it.
This trial tests an oral tablet (SYH2085) to see if it can help adults with the flu feel better faster. If you join, you'll either get the study drug or a placebo (a pill with no medicine).
This study tests an experimental medicine called TRX-100 to see if it can safely treat the flu. Healthy volunteers will be given the flu virus in a controlled setting, then the medicine, to see how well it works.
This study tests an experimental flu vaccine (BPL-1357) in healthy volunteers who will later be exposed to H1N1 flu virus in a controlled setting, to see if the vaccine can prevent or reduce illness.
Hear when a new Influenza, Human trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.